Plasma cell myeloma

Researchers are testing a vaccine called 3D189 in adults with blood cancers such as acute leukemia, multiple myeloma, non-Hodgkin lymphoma, and higher-risk myelodysplastic syndrome. Participants must be in remission after standard treatment and unable to receive a stem cell trans…

Researchers compare two three-drug combinations, VTD and VCD, as initial treatment for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. Participants receive four cycles of either combination. The trial measures how well each combination re…

Researchers are testing a combination of carfilzomib, melphalan, and prednisone in adults over 65 with newly diagnosed multiple myeloma. The trial first aims to find the highest dose of carfilzomib that people can tolerate without severe side effects. Then it will measure how wel…

Researchers are testing whether adding the experimental drug MLN9708 to lenalidomide and dexamethasone can help adults under 66 with newly diagnosed multiple myeloma. Participants receive three cycles of the triplet, then a stem cell transplant, followed by more triplet and maint…

This phase 2 trial tests a combination of four drugs, selinexor, bortezomib, lenalidomide, and dexamethasone (SVRd), in people newly diagnosed with multiple myeloma whose disease has spread outside the bone marrow, called extramedullary disease. The study aims to see how well thi…

This Phase II study tests a treatment plan using daratumumab (Darzalex) and dexamethasone for adults aged 65 and older with newly diagnosed multiple myeloma who cannot handle intensive chemotherapy. The goal is to see how well the combination controls the disease by measuring res…

This phase 2 study tested a sequence of four drugs—carfilzomib, clarithromycin, lenalidomide, and dexamethasone—in 74 people newly diagnosed with multiple myeloma. The goal was to see how safe and effective this combination is at controlling the disease. Participants first receiv…

This study tests a new approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Patients receive a combination of umbilical cord blood and stem cells from a family member, with the cord blood chosen based on specific genetic markers rather than …

This early-phase trial tested whether giving patients their own natural killer (NK) cells, boosted by the drug bortezomib, is safe for treating advanced cancers like leukemia, lung, and pancreatic cancer. Thirty-five adults whose cancers had not responded to standard treatments r…

This trial is testing whether a chemotherapy drug called treosulfan, given in different doses along with fludarabine, can safely prepare patients with advanced blood cancers for a stem cell transplant. The study focuses on patients who are not eligible for the standard, more inte…

This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…

This phase III trial is testing whether adding selinexor to a standard two-drug regimen (bortezomib and dexamethasone) can help people with relapsed or refractory multiple myeloma—a blood cancer that has returned or stopped responding to treatment. About 154 adults with measurabl…

This trial tests whether stem cells grown in the lab before being returned to the body can help blood counts recover faster after a stem cell transplant for multiple myeloma. Adults aged 18 to 65 with myeloma in first response will receive their own amplified stem cells. The main…

This study tracks adults with relapsed or refractory multiple myeloma who are already receiving isatuximab as part of their routine care. Researchers will measure how many patients respond to treatment, how long the response lasts, and how the drug affects quality of life and sid…

This study tested whether the drug siltuximab can lessen the severity of cytokine release syndrome (CRS) and neurological side effects (ICANS) that often occur after CAR-T cell therapy for blood cancers like lymphoma and leukemia. Twenty-four participants received siltuximab alon…

This early-stage study tests an experimental pill called LOXO-338 in 316 adults with advanced blood cancers like leukemia, lymphoma, or multiple myeloma. Participants have already tried standard treatments. The main goals are to find the safest dose and see if the drug shrinks tu…

This Phase 3 trial tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers. The goal was to see if this approach could help patients who don't have a fully matched donor. Participants received chemoth…

This study looks at two treatments—plasma exchange (a blood-filtering procedure) and the drug daratumumab—to see if they help patients with multiple myeloma recover from acute kidney injury caused by light chain cast nephropathy. Researchers will track 450 adults to see who survi…

This early-phase study tests a combination of two drugs—TTI-622 and daratumumab—in people whose multiple myeloma has returned or is not responding to treatment. The main goal is to find a safe dose of TTI-622 when given with daratumumab. Only 7 participants are enrolled, so the f…

This study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…

This early-phase study tests a new treatment for multiple myeloma that has returned or stopped responding to prior therapies. It combines specially engineered natural killer (NK) cells (called TiNK) with an antibody drug (isatuximab) and standard chemotherapy. The main goal is to…

This pilot study tested whether the multiple myeloma drug carfilzomib can be safely given at home instead of in a hospital. Seventeen patients received their first cycle in the clinic and later cycles at home, with nurses administering the short infusion. The main goal was to see…

This phase 2 trial tested nivolumab, an immunotherapy drug, in 20 people with blood cancers like lymphoma, leukemia, or myeloma that came back or didn't respond after CAR T-cell therapy. The goal was to see if nivolumab could help the immune system attack the cancer again. The st…

This phase 3 trial is testing whether adding daratumumab (a targeted antibody) to standard lenalidomide maintenance therapy can clear remaining cancer cells in people with multiple myeloma who still have minimal residual disease after a stem cell transplant. About 200 participant…

This study tested a drug called ixazomib, alone or with other medicines, in 165 people whose multiple myeloma (a blood cancer) had come back. The goal was to see if these combinations could shrink or control the cancer. Participants received different treatment plans, and doctors…

This phase 3 trial tests whether a personalized cell therapy called bb2121 works better than standard drug combinations for people with relapsed and refractory multiple myeloma. About 386 participants were randomly assigned to receive either bb2121 or one of several standard regi…

This phase II trial tested the drug imetelstat in 13 patients with multiple myeloma who had stable disease or partial response after prior therapy but not a complete remission. The goal was to see if adding imetelstat could improve their response. Patients received imetelstat int…

This study looked at whether denosumab, a drug usually used for bone health, could safely reduce the risk of smoldering multiple myeloma turning into active multiple myeloma. Twenty people with smoldering multiple myeloma took part. The goal was to see if the drug could lower the…

This study tested two drug combinations in 186 adults with multiple myeloma that came back or didn't respond after earlier treatment. One group got pomalidomide plus low-dose dexamethasone, and another got those two plus daratumumab. The goal was to see if the tumors shrank enoug…

This early-phase trial tested a new gene therapy for multiple myeloma, a blood cancer that often becomes resistant to standard treatments. Researchers took participants' own immune T cells, modified them in the lab to recognize a protein called BCMA on myeloma cells, and infused …

This trial studies a combination of the investigational antibody isatuximab with the drugs carfilzomib and dexamethasone for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find the safest dose and see how well the body…

This early-phase study tested whether specially grown immune cells (cytokine-induced killer cells) could safely treat blood cancers that return after a stem cell transplant. 21 adults with relapsed multiple myeloma or other blood cancers received these donor cells. The goal was t…

This phase 2 study tested a combination of two chemotherapy drugs, busulfan and melphalan, given before an autologous stem cell transplant in 78 people with newly diagnosed multiple myeloma. All participants had already received a bortezomib-based induction therapy and then took …

This study tested teclistamab, a drug that helps the immune system find and attack myeloma cells, in 40 Japanese patients whose multiple myeloma had returned or stopped responding to treatment. The goal was to check safety and find the right dose in phase 1, then see how well it …

This phase 3 study tested whether adding daratumumab to a standard three-drug regimen (bortezomib, lenalidomide, dexamethasone) helps people with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. The main goal was to see if more patients achieve a …

This early-phase trial tested a combination of two drugs—selinexor and choline salicylate (a type of aspirin)—in 22 adults with certain lymphomas or multiple myeloma that had come back or not responded to treatment. The main goal was to find the safest dose and check for side eff…

This study tested a treatment called anti-BCMA CAR T-cell therapy in 40 adults with multiple myeloma whose disease did not respond well enough to a stem cell transplant and maintenance therapy. The goal was to see if this one-time cell therapy could help more patients achieve a c…

This study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims …

This phase II trial tested a combination of pomalidomide and dexamethasone in 84 patients with advanced multiple myeloma whose cancer had worsened despite treatment with bortezomib and lenalidomide. The goal was to see if this drug pair could shrink tumors and control the disease…

This early-phase study tested a new type of CAR T cell therapy, called ALLO-715, made from donor cells (not the patient's own). It was given to 73 adults with multiple myeloma that had come back or stopped responding to at least three prior treatments. The goal was to check safet…

This study tested a combination of two drugs, busulfan and bortezomib, given before a second stem cell transplant in 30 patients with multiple myeloma that had returned after a previous transplant. The goal was to see if this approach could control the disease. Results showed tha…

This study tested a daily supplement of curcumin (from turmeric) and piperine (from black pepper) in 30 people with early-stage prostate cancer or pre-cancerous blood conditions (MGUS or low-risk smoldering multiple myeloma). The goal was to see if the supplement could lower canc…

This study looked at how safe and tolerable the drug Kyprolis is for Indian patients whose multiple myeloma has come back or stopped responding to treatment. A total of 101 adults took part, and researchers tracked side effects and how long the drug kept the cancer from getting w…

This study tested a two-step treatment for people whose multiple myeloma returned after a donor stem cell transplant. First, patients received lenalidomide and dexamethasone to reduce cancer and prepare the immune system. Then, they received donor immune cells (lymphocyte infusio…

This study tested different dosing schedules of the drug belantamab mafodotin in 177 adults with multiple myeloma that had returned or stopped responding to at least three prior treatments. The goal was to see if changing the dose or how often it is given could reduce serious eye…

This study tested a new drug called REGN5459 in 43 people with multiple myeloma that had returned or stopped responding to other treatments. The drug works by helping the immune system attack cancer cells. The main goals were to check safety and find the best dose, and to see how…

This study tested a drug called daratumumab in 49 people with multiple myeloma who were eligible for a stem cell transplant. The goal was to see if daratumumab could help eliminate any remaining cancer cells in the bone marrow after the transplant. While the treatment aims to con…

This study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…

This study tested adding elotuzumab to a standard three-drug combination (bortezomib, lenalidomide, dexamethasone) for people newly diagnosed with high-risk multiple myeloma, a blood cancer that tends to come back quickly. The goal was to find the safest dose of elotuzumab and se…

This phase 2 trial tested a combination of three drugs—carfilzomib, lenalidomide, and dexamethasone—given before and after a stem cell transplant in 76 people newly diagnosed with multiple myeloma. The goal was to see how many patients achieved a very deep remission (stringent co…

This phase 2 trial tested three different schedules of the drug daratumumab in 123 people with smoldering multiple myeloma, a condition that often progresses to active multiple myeloma. The goal was to see how well each schedule controlled the disease and led to complete response…

This study tested different combinations of cancer drugs (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) in 477 adults newly diagnosed with multiple myeloma who were eligible for a stem cell transplant. The goal was to see which combination worked best before and…

This study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…

This study offers continued treatment with elotuzumab (plus dexamethasone) to 67 multiple myeloma patients who were already benefiting from it in earlier trials. The main goal is to keep providing the drug and track how long patients stay on treatment. Researchers will also monit…

This early-stage trial tested a new drug called forimtamig in 225 people with multiple myeloma that had returned or stopped responding to standard treatments. The main goals were to check safety and find the right dose. Participants received the drug by IV or injection, and resea…

This study tested whether adding the drug bortezomib to the standard chemotherapy before a donor stem cell transplant could help people with multiple myeloma live longer without their cancer getting worse. Fifty-four adults received the new drug combo. The main goal was to see if…

This phase 2 trial tested a three-drug combination (carfilzomib, lenalidomide, and dexamethasone) followed by a stem cell transplant and maintenance therapy in 46 newly diagnosed multiple myeloma patients aged 65 or younger. The goal was to see if this intensive approach could le…

This phase 1b trial tested the safety of adding TAK-079 (Mezagitamab) to standard treatments for 50 people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal was to find the right dose and watch for side effects. Researchers also tracked how we…

This study tested a personalized geriatric optimization plan (GO!) in 30 adults aged 60 and older who were getting a donor stem cell transplant for blood cancers or bone marrow failure. The plan included tailored advice on diet, sleep, activity, and medications to improve physica…

This study tested a drug called CT-011 (a PD-1 blocker) and a dendritic cell vaccine given after a stem cell transplant in 35 people with multiple myeloma. The goal was to see if this combination is safe and can boost the immune system to fight remaining cancer cells. Researchers…

This study looked at 700 adults up to age 65 with multiple myeloma to see if high-dose therapy with a stem cell transplant works better than standard drug therapy (lenalidomide, bortezomib, and dexamethasone). The goal was to find out which approach delays the cancer from growing…

This phase 2 study tested a weekly dose of the drug carfilzomib combined with two standard chemotherapy drugs (melphalan and prednisone) in 32 elderly patients (65 years or older) with newly diagnosed multiple myeloma. The goal was to find the safest effective dose and see how we…

This phase 3 trial tested whether taking lenalidomide (Revlimid) after an autologous stem cell transplant helps people with myeloma stay in remission longer. Over 600 participants under age 65 who had no signs of progression after transplant were randomly assigned to receive lena…

This study tested a drug called daratumumab combined with dexamethasone in 64 people with multiple myeloma that had stopped responding to three other treatments. The goal was to see how many patients' tumors shrank or disappeared. The treatment is not a cure, but aims to control …

This study tested a combination of thalidomide, bortezomib, and high-dose melphalan followed by a stem cell transplant in 29 patients with advanced multiple myeloma who had already failed one round of treatment. The goal was to find the safest dose of thalidomide and see how well…

This study tested whether adding a drug called vorinostat to the standard combination of lenalidomide and dexamethasone could help patients whose multiple myeloma had stopped responding to lenalidomide. The trial enrolled 25 adults with relapsed or refractory multiple myeloma. Th…

This phase 2 trial tested a two-step stem cell transplant approach for 47 patients with high-risk blood cancers like leukemia and lymphoma. The method uses the drug cyclophosphamide to lower the chance of graft-versus-host disease (GVHD), a common complication. The goal was to se…

This study tested a new way to treat high-risk multiple myeloma using umbilical cord blood that was expanded in the lab with a molecule called UM171. Nineteen patients received this special transplant to see if it was safe and could help control the disease. The goal is to improv…

This study tested a new drug called daratumumab, given together with two standard treatments (lenalidomide and dexamethasone), in 45 people whose multiple myeloma had returned or stopped responding to prior therapy. The main goal was to check safety and see how many patients resp…

This phase 2 pilot study tested a combination of three drugs—carfilzomib, lenalidomide, and dexamethasone—in 55 people with high-risk smoldering multiple myeloma, a condition that often leads to active myeloma. The goal was to see if the treatment could eliminate signs of the dis…

This study tested a therapy called bb2121, made from a patient's own immune cells that are reprogrammed to attack myeloma cells. It included over 300 people with multiple myeloma that had returned or was high-risk. The goal was to see if the treatment could shrink tumors and cont…

This pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection dr…

This study tested a combination of four drugs (elotuzumab, carfilzomib, lenalidomide, and dexamethasone) in 15 people whose multiple myeloma had returned or stopped responding to treatment. The goal was to see if this experimental mix could shrink the cancer more effectively than…

This study tested a new way to treat multiple myeloma by starting with just two drugs (bortezomib and dexamethasone) and adding a third (lenalidomide) only if the disease wasn't well controlled. The goal was to see if this step-by-step approach could achieve the same good results…

This study tested a new drug called MK-7684A, which combines two immune-boosting medicines (pembrolizumab and vibostolimab), in 192 people with blood cancers like lymphoma and multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to see…

This study tested whether a shot under the skin (subcutaneous) works as well as an IV drip for the drug isatuximab in people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. All participants also received standard chemotherapy. The goal was to se…

This study tested the drug denosumab in 55 people with multiple myeloma and severe kidney problems. The goal was to see if it could help control bone damage caused by the cancer. Researchers measured changes in bone turnover markers and monitored side effects like low calcium and…

This early-phase trial tested a new CAR-T cell therapy called C-CAR088 in 9 patients with multiple myeloma that had returned or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to target a protein called BCMA on myeloma cells. The main goal…

This phase 2 study tests whether a new drug called GPC-100, combined with propranolol and with or without G-CSF, can effectively mobilize stem cells in people with multiple myeloma who are preparing for an autologous stem cell transplant. The goal is to see if enough stem cells c…

This early-stage trial tested a new cell therapy called CC-95266 in 130 people with multiple myeloma that had come back or stopped responding to treatment. Participants also received chemotherapy drugs to prepare their bodies for the cell infusion. The main goals were to check sa…

This study tested whether adding the drug isatuximab to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with multiple myeloma that has returned or stopped responding to prior treatments. 302 adults who had already received 1 to 3 prior therapies took part…

This study tested a new way of giving the drug elranatamab to people with multiple myeloma that came back or didn't respond to treatment. The drug was given as a shot under the skin, starting with low doses and then increasing, with longer breaks between doses over time. The goal…

This early-phase trial tested a new drug called cevostamab in 355 people with multiple myeloma that had returned or stopped responding to other treatments. The main goal was to check the drug's safety and find the right dose. While it may help control the disease, it is not a cur…

This study tested a combination of pomalidomide and dexamethasone in 63 patients with multiple myeloma that had returned or stopped responding to treatment, and who had specific high-risk genetic changes. The goal was to see how well the drugs controlled the disease and what side…

This study tested a new version of the chemotherapy drug melphalan (EVOMELA) combined with fludarabine and total body irradiation before a half-matched (haploidentical) stem cell transplant in 43 adults with blood cancers like multiple myeloma. The goal was to see if this approac…

This early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…

This study looked at 42 people with multiple myeloma that was still present after a stem cell transplant. It compared continuing lenalidomide alone versus adding two other drugs (ixazomib and dexamethasone) to try to eliminate the remaining cancer. The goal was to see which appro…

This phase 2 trial tested a combination of four drugs—elotuzumab, carfilzomib, lenalidomide, and dexamethasone—in 46 people newly diagnosed with multiple myeloma. The goal was to see how many patients achieved a very deep response (stringent complete response or minimal residual …

This completed Phase 2 study tested a combination of three drugs—lenalidomide, bortezomib, and dexamethasone (RVD)—in 46 people newly diagnosed with multiple myeloma. The goal was to see how well the drugs worked before a stem cell transplant. The study measured response rates an…

This study tested whether giving two drugs—ixazomib and lenalidomide—in an alternating schedule after a stem cell transplant could safely delay the return of multiple myeloma. Thirty patients who had already received a transplant took part. The main goal was to check for side eff…

This study tested different drug combinations in 1,503 adults aged 18-65 with newly diagnosed multiple myeloma. The goal was to see which approach—standard drugs or high-dose chemo with stem cell transplant—works better to delay the cancer's return. Patients received maintenance …

This study tested a drug called elranatamab in 39 Chinese patients with multiple myeloma that had stopped responding to at least three prior treatments. The drug works by helping the immune system attack cancer cells. The goal was to see if it could shrink tumors and control the …

This early-phase study tested a combination of three drugs—ibrutinib, lenalidomide, and dexamethasone—in 14 people with multiple myeloma that had come back or stopped responding to prior treatments. The main goal was to find safe doses and watch for side effects. Results help gui…

This study tested a combination of three drugs (pomalidomide, dexamethasone, and carfilzomib) in 25 people with multiple myeloma that had come back or stopped responding to prior treatments. The goal was to find the safest dose and see how well the drugs worked together to contro…

This phase 3 study tested whether adding daratumumab to standard pomalidomide and dexamethasone helps people with relapsed or refractory multiple myeloma live longer without their disease getting worse. 304 adults who had already tried lenalidomide and a proteasome inhibitor took…

This study tested whether a stem cell transplant from a matched donor could improve outcomes for myeloma patients under 65 who had already responded well to their own stem cell transplant. Thirteen patients received a reduced-intensity conditioning regimen followed by the donor t…

This study looked at whether patients with multiple myeloma or non-Hodgkin lymphoma could safely skip a drug called tbo-filgrastim after a stem cell transplant and still recover quickly. The drug is normally given to boost white blood cells. The trial compared two groups: one tha…

This phase 2 trial tested a three-drug combination (ixazomib, cyclophosphamide, and dexamethasone) in 112 patients with multiple myeloma that had returned or stopped responding to three previous treatments. The goal was to see if adding ixazomib to standard chemotherapy could hel…

This early-stage trial tested a new therapy called FT576, made from specially engineered stem cells that become cancer-fighting immune cells. It was given alone or with another drug, daratumumab, to 31 people with multiple myeloma that had returned or stopped responding to prior …

This early-stage study tested a combination of two drugs, acalabrutinib and ACP-319, in 40 people with B-cell cancers such as non-Hodgkin lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. The goal was to check safety and how well the drugs work together. Partic…

This early-phase study tested a new drug combination (duvelisib plus BMS-986345) in 14 people with blood cancers like lymphoma, myeloma, and leukemia. The main goal was to find a safe dose and check for side effects. Researchers also looked at how well the cancer responded after …

This study tested a combination of three drugs—pomalidomide, cyclophosphamide, and dexamethasone—in 100 patients with multiple myeloma that had returned after initial treatment. All patients had previously been part of the IFM/DFCI 2009 trial. The goal was to see how many patient…

This study tested a combination of three drugs—carfilzomib, lenalidomide, and dexamethasone—in 29 people newly diagnosed with multiple myeloma. The goal was to find the safest high dose of carfilzomib and see how well it clears cancer cells from the body. Researchers measured sid…

This early study tested whether removing a specific type of immune cell (regulatory T cells) is safe in 30 people with multiple myeloma undergoing a stem cell transplant. Participants received standard transplant drugs plus a procedure to deplete these cells. The goal was to see …

This early-phase trial tested a combination of three drugs—selinexor, carfilzomib, and dexamethasone—in 52 patients with multiple myeloma that had returned or stopped responding to treatment. The main goal was to find the safest dose and check for side effects. Researchers hope t…

This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…

This study tested the drug nivolumab (Opdivo), alone or combined with other drugs, in 320 people with relapsed or refractory non-Hodgkin lymphoma, Hodgkin lymphoma, or multiple myeloma. The main goal was to check safety and side effects, especially for the nivolumab plus daratumu…

This early-phase study tested a combination of high dose vitamin C and a low dose of the chemotherapy drug melphalan in 6 patients with multiple myeloma that had stopped responding to other treatments. The main goal was to check safety, and researchers also looked for signs that …

This phase 3 study compared a three-drug combination (daratumumab, lenalidomide, and dexamethasone) against the standard two-drug regimen (lenalidomide and dexamethasone) in 737 people with newly diagnosed multiple myeloma who could not undergo high-dose chemotherapy and stem cel…

This phase 2 trial tested a combination of three drugs—ixazomib, cyclophosphamide, and dexamethasone—as a first treatment for multiple myeloma. The goal was to see if this mix works better and causes fewer nerve problems than standard options. Twelve newly diagnosed patients took…

This completed study tested a combination of three drugs—bortezomib, lenalidomide, and dexamethasone (VRD)—in 419 newly diagnosed multiple myeloma patients. Some patients also received a stem cell transplant. The goal was to see how well the treatment worked and how long patients…

This study tested whether a combination of two drugs, cyclophosphamide and abatacept, could lower the risk of chronic graft-versus-host disease (GVHD) after a stem cell transplant in people with high-risk blood cancers. GVHD happens when donor cells attack the patient's body. The…

This study tested a combination of three drugs (pomalidomide, ixazomib, and dexamethasone) with or without a fourth drug (cyclophosphamide) in 66 adults with multiple myeloma that had come back or stopped responding to treatment. The goal was to see how well the treatment control…

This study tested whether the drug palifermin could make stem cell transplants safer and reduce chronic graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Thirty-four adults with blood cancers received palifermin before transplan…

This study tested two different drug combinations to collect stem cells from 62 multiple myeloma patients before a stem cell transplant. The goal was to see which method works better and causes fewer side effects. Results could help more patients successfully move forward with tr…

This early-phase trial tested a new drug called Purinostat Mesylate in 29 people with relapsed or refractory B-cell lymphomas, a type of blood cancer. The main goals were to check safety, find the right dose, and see how the drug moves through the body. Researchers hope this drug…

This early-phase study tested a new drug called JNJ-64407564 in 15 Japanese patients with multiple myeloma that had come back or stopped responding to other treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goal was to …

This study tested whether fasting for at least 14 hours each night could help overweight people with early blood cancer conditions (MGUS, smoldering myeloma) lose weight and possibly lower their cancer risk. Twenty-three participants were randomly assigned to either the fasting p…

This study tested a combination of two drugs, plerixafor and G-CSF, to help collect stem cells from the blood of 53 people with multiple myeloma. The goal was to see if this approach could gather enough healthy stem cells for a transplant in fewer sessions. Results showed the com…

This phase 2 trial tested a powerful combination of chemotherapy drugs followed by stem cell transplants in 40 patients under 70 with primary plasma cell leukemia, a rare and aggressive blood cancer. The goal was to see if this intensive approach could improve how long patients l…

This study tested a two-step (tandem) stem cell transplant in 148 people with multiple myeloma. Patients received high-dose melphalan chemotherapy, followed by a second transplant with melphalan plus bortezomib (Velcade). The goal was to see if this approach could delay cancer pr…

This early-stage trial tested a new therapy called SUPLEXA in 46 adults with advanced solid tumors or blood cancers that had spread. SUPLEXA is made from a patient's own immune cells, which are processed in a lab to become more active against cancer. The main goal was to check sa…

This early-stage trial tested an experimental drug called SAR442085 in 37 people with multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to find a safe dose and check for any signs that the drug shrinks tumors. Participants received …

This study tested two ways to treat multiple myeloma that has come back or stopped responding to treatment. All 23 participants first received a combination of clarithromycin, pomalidomide, and dexamethasone. Then, half got a stem cell transplant followed by pomalidomide, while t…

This study tested a drug combination (isatuximab, pomalidomide, and dexamethasone) in 56 patients with multiple myeloma that had returned or stopped responding to prior treatments. The main goal was to see if giving isatuximab as a shot under the skin works as well as giving it t…

This early-phase study tested whether repeated hyperbaric oxygen therapy is safe for multiple myeloma patients who are about to receive high-dose chemotherapy and a stem cell transplant. Twenty-nine participants were exposed to 100% oxygen at 2.5 times normal atmospheric pressure…

This phase 2 study tested a combination of three drugs—carfilzomib, pomalidomide, and dexamethasone—in 54 adults whose multiple myeloma had come back after one or two prior treatments. The goal was to see how many patients responded to the therapy. The study is complete, and resu…

This phase 2 trial tested a drug called belantamab mafodotin in 221 people with multiple myeloma that had not responded to at least three prior treatments. The drug is an antibody-drug conjugate that delivers a toxin directly to cancer cells. Participants received one of two dose…

This early-phase trial tested a new drug called PTX-100 in 25 people with advanced cancers like multiple myeloma, lymphoma, and certain solid tumors. The goal was to find safe doses and understand how the drug behaves in the body. Participants received the drug by IV for five day…

Researchers compare PET scans and MRI to see which imaging method detects more myeloma lesions in adults under 65 with newly diagnosed multiple myeloma. Participants receive both scans at diagnosis, after three cycles of chemotherapy, and at the end of treatment. The study also t…

This completed early-phase study tested a new radioactive tracer called 18F-BL40 for PET/CT scans in 10 adults with certain blood cancers (like lymphoma and leukemia). The goal was to see if it safely and accurately detects tumors by targeting a receptor common in many cancers. R…

This study compares two types of PET/CT scans—one using a standard tracer (FDG) and another using a newer tracer (FCH)—to see which detects more bone lesions in people newly diagnosed with multiple myeloma. Twenty participants will receive both scans and an MRI within three weeks…

This phase 3 trial tested whether a biologic called IMM-101 could reduce severe respiratory infections, including COVID-19, in cancer patients at higher risk. 195 participants either received three doses of IMM-101 or were simply observed. The goal was to see if the treatment cou…

This trial tests whether personalized education from a nurse can help people newly diagnosed with multiple myeloma better handle side effects from the drug bortezomib. Participants receive either standard care or two one-on-one teaching sessions covering symptoms like nerve pain,…

This study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …

This study explored whether multiple myeloma patients could safely administer the drug Carfilzomib at home instead of always going to the hospital. Nine patients who had already received at least one treatment cycle in the clinic were taught to give themselves the infusion on cer…

This study tested whether roasted nux vomica capsules can help with nerve pain caused by the chemotherapy drug bortezomib in multiple myeloma patients. Twenty-two participants took the capsules for six weeks while continuing their regular chemo. Researchers measured changes in ne…

This study tested a structured educational program called the Myeloma Pack for people with multiple myeloma. The goal was to see if it could reduce anxiety and depression and improve quality of life. 85 patients took part while receiving standard cancer treatment. Researchers mea…

This study tested a set of dermo-cosmetic products (hand/foot serum, nail strengthener, dissolving oil, and gloves/slippers) in 20 multiple myeloma patients receiving bispecific antibody therapy. The goal was to see if these natural-based products could prevent or reduce skin and…

This study tested an online educational program for cancer patients receiving chemotherapy. The program included video sessions, peer discussions, and digital materials to help with symptom management and emotional coping. Researchers compared 212 patients who used the program to…

This study looked at whether providing free blood transfusions to blood cancer patients would encourage them to enroll in hospice care earlier. Many patients delay hospice because they need transfusions for symptom relief, but hospices often cannot afford to provide them. The stu…

This study looked at whether starting supportive care (like meetings with a nurse, psychologist, or dietitian) right after a multiple myeloma diagnosis helps patients feel better compared to waiting 6 months. Twenty patients took part, and researchers measured their quality of li…

This study tested whether neuromuscular electrical stimulation (NMES) can help Veterans with blood cancers maintain physical function and reduce fatigue during stem cell transplant. 46 participants used NMES while in the hospital. The goal was to see if this approach could preven…

This pilot study tested a 6-session exercise and activity program called Health Through Activity (HTA) in 5 adults with multiple myeloma who were on maintenance therapy and had trouble with daily activities due to their health. The goal was to see if the program was feasible and …

This study tested whether giving Darzalex Faspro (a drug for multiple myeloma) at home is practical and satisfactory for patients. Twenty adults with multiple myeloma who were already on a monthly daratumumab regimen received their injections at home. The main goal was to measure…

This study tested whether distance Reiki—a hands-off energy therapy—could improve quality of life and immune function in 30 adults with multiple myeloma who had a stem cell transplant. Participants received real Reiki, fake Reiki, or no extra care. The goal was to see if Reiki he…

This study tested whether wearing a special cooling cap during chemotherapy can prevent hair loss in people with multiple myeloma getting a stem cell transplant. 31 participants used the Penguin cold caps. The goal was to see if at least 75% of people kept more than half their ha…

This study tested whether colesevelam, a drug used for high cholesterol, can safely reduce diarrhea in people with multiple myeloma who take lenalidomide. 25 participants received colesevelam for 4 weeks. The goal was to see if diarrhea improved to a mild level or better. The stu…

This pilot study tested a pain management program for cancer survivors living in rural areas or of Hispanic background. The program included acupuncture, cognitive behavior therapy, educational materials, and a pain clinic referral. The goal was to see if the program was feasible…

This study tested whether using augmented virtual reality (AVR) during chemotherapy can help reduce pain, stress, and anxiety while boosting self-confidence. 150 adult cancer patients in the West Bank were split into two groups: one received standard care, and the other used AVR …

This study tested whether a battery-powered drill could make bone marrow biopsies less painful and produce better samples than the traditional manual needle. 100 patients with plasma cell disorders took part. Researchers measured pain levels and the quality of the biopsy sample.

This study tests a new way to choose treatments for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to standard therapy. Researchers use a lab test that checks many drugs at once, along with genetic information, to find which drug or d…

This completed study analyzed genetic material from 1,340 patients with lymphoma, leukemia, or multiple myeloma. Researchers used DNA microarrays and other tools to find new molecular subtypes that could explain why some patients respond better to treatment than others. The goal …

Researchers are using wearable sensors and smartphone check-ins to track fatigue as it happens in people with myeloma, long COVID, heart failure, and healthy controls. Participants wear an ECG patch and a wrist sensor that measure heart rate, activity, and posture, and they rate …

This study looked at nearly 1,900 male farmers over age 50 to see if pesticide exposure is linked to early signs of blood cancers like multiple myeloma. Researchers collected blood and urine samples and compared those with and without exposure to the pesticide diazinon. No treatm…

This study will analyze the genetic makeup of tumors from 100 people with relapsed multiple myeloma. Researchers will use advanced DNA and RNA sequencing to find genetic changes and understand how the cancer works. The goal is to gather information that could guide more personali…

Multiple myeloma, a common blood cancer, often causes bone lesions that lead to pain, fractures, and other serious events. This study reviews medical records of patients diagnosed between 2019 and 2021 to describe how often these bone complications occur and what rehabilitation s…

This study tests a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) designed to help doctors see how diverse their clinical trial enrollments are. The goal is to overcome racial and ethnic disparities in leukemia trial participation. The study enroll…

This study is not testing a new treatment. Instead, researchers in Italy are observing how doctors currently treat a tough form of multiple myeloma that no longer responds to three main drug classes. They will collect information from medical records of about 250 patients across …

This study looks back at medical records of over 300 adults with relapsed/refractory multiple myeloma to compare how well different drug combinations work in everyday practice. Researchers are analyzing outcomes like how long patients live without their cancer worsening and overa…

This study aims to develop a standardized reference guide for pharmacists to use during initial consultations with multiple myeloma patients starting oral chemotherapy. The goal is to provide clear, consistent information that helps patients understand and follow their treatment …

This completed study looked at 70 patients with myeloma or lymphoma who needed stem cell transplants. Researchers compared two drugs, Zarzio and Granocyte, used to stimulate stem cell production before collection. The goal was to see if one drug led to better stem cell grafts. Si…

This study looked back at medical records of 100 adults with multiple myeloma that had returned after initial treatment. Researchers compared how long patients stayed cancer-free on four different three-drug combinations. The goal was to see which combination worked best in real-…

This study followed over 900 newly diagnosed multiple myeloma patients who were not eligible for a stem cell transplant. Researchers compared heart-related side effects between those treated with lenalidomide (Revlimid) and those receiving other treatments. The goal was to better…

This study monitored 201 people with multiple myeloma to see how well COVID-19 vaccines and boosters work for them. Since their immune systems are weaker, researchers wanted to learn if vaccines still provide good protection. The goal was to find better ways to keep this vulnerab…

This study interviewed 9 people with multiple myeloma who had received at least 5 different treatments. The goal was to learn about their experiences and what factors are most important to them when deciding on a treatment. No new drugs or therapies were tested; instead, the stud…

This study looked at whether an exercise program is practical for people aged 65 and older with blood cancers like lymphoma, leukemia, or myeloma who are about to receive CAR T-cell therapy. The program included remote exercise sessions and was tested with 20 participants to see …

This study looked at the safety of the drug Ninlaro (ixazomib) when used to treat multiple myeloma in everyday medical practice in China. About 482 patients were observed, and researchers recorded any side effects or dose changes. The goal was to gather real-world safety informat…

This study measured certain proteins in the blood and urine of 20 newly diagnosed multiple myeloma patients before and 30 days after starting daratumumab. The goal was to see if these markers could help detect early kidney injury. Participants provided samples during routine lab …

This study looked at whether newer imaging techniques can better detect when a person with early blood conditions (MGUS or smoldering myeloma) is developing active multiple myeloma. Thirty-one adults with these conditions received three types of scans: a standard PET/CT, an exper…

This study looked at 56 older adults (65+) with multiple myeloma to see if a comprehensive geriatric assessment—a series of questions and tests about physical and mental health—along with blood tests could predict who would have serious side effects from chemotherapy. The goal is…

This study looked at 66 people with multiple myeloma to find out how many also have a condition called autoimmune hemolytic anemia (AIHA), where the body attacks its own red blood cells. Researchers measured how common AIHA is in these patients and whether it affects their progno…

This study explored whether a simple blood test (liquid biopsy) and a whole-body MRI can detect leftover cancer cells in people with multiple myeloma, potentially replacing the need for a bone marrow biopsy. Researchers enrolled 36 adults with newly diagnosed or previously treate…

This study looked at how well the Pfizer COVID-19 vaccine triggers an immune response in 196 adults with weakened immune systems (due to conditions like kidney transplant, cancer, or HIV) compared to healthy adults. Researchers measured antibody levels and their ability to neutra…

This completed study looked at whether the COVID-19 vaccine triggers a strong immune response in 146 people with multiple myeloma or Waldenstrom's macroglobulinemia. Researchers measured antibody levels 28 days after the final vaccine dose. The goal was to see if these patients, …

This study looked at how faithfully adults with multiple myeloma (a type of blood cancer) follow their prescribed carfilzomib combination treatments in everyday medical practice. It included 359 patients who had already tried at least one prior therapy. The goal was to measure ad…

This study looked at whether a substance called M-CSF in the blood can help identify bone lesions in people with multiple myeloma. Researchers compared M-CSF levels in 111 participants: those with multiple myeloma, those with a pre-cancer condition called MGUS, and healthy contro…

This study examined whether three blood measurements—blood thickness (viscosity), the balance of two proteins (albumin/fibrinogen ratio), and red blood cell size variation (RDW)—can help predict how newly diagnosed multiple myeloma patients will fare over the next year. Researche…

This study surveyed 218 adults with chronic lymphocytic leukemia or multiple myeloma to measure how often treatment causes financial difficulty. Patients answered questions about money worries over the past year. The goal was to identify common financial burdens and what resource…

This pilot study tested whether a plant-based whole-foods meal delivery service is practical for multiple myeloma patients receiving an autologous stem cell transplant. The goal was to see if patients would eat the meals and if it could improve gut microbiome diversity, which is …

This study collected blood samples from nearly 1,900 people in families where at least two members have a type of dysglobulinemia, including multiple myeloma, MGUS, or Waldenström's disease. Researchers will analyze the DNA to look for genetic variations that might increase the r…

This completed study involved 146 patients with blood cancers who received a stem cell transplant from a donor. Researchers collected blood and tissue samples over a year to study immune cells linked to graft-versus-host disease (GVHD), a common complication where donor cells att…